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Summary Patients with aplastic anemia or hypoplas-
tic myelodysplastic syndrome (MDS) may respond
to immunosuppressive therapy, including the anti-
CD52 antibody alemtuzumab. We analyzed treatment
responses to alemtuzumab in 5 patients with MDS
or aplastic anemia (AA) evolving to MDS. Two pa-
tients with hypoplastic MDS (hMDS) showed a partial
response (PR) to alemtuzumab. In both respond-
ing patients, a concomitant paroxysmal nocturnal
hemoglobinuria (PNH) clone was detected before
therapy. One responder relapsed after 15 months and
underwent successful allogeneic stem cell transplan-
tation. Both patients are still alive and in remission
after 40 and 20 months, respectively. The other pa-
tients showed no response to alemtuzumab. One pa-
tient died from pneumonia 4 months after treatment.
In summary, our data confirm that alemtuzumab is
an effective treatment option for a subset of patients
with MDS, even in the presence of a PNH clone.
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Introduction
Specific therapeutic options for patients suffering
from AA and hMDS are limited. One treatment option
is immunosuppressive therapy (IST) [1–4]. Although
various forms of IST have been suggested, treatment
with anti-thymocyte globulin (ATG) combined with
cyclosporine A (CSA) is regarded first-line standard in
older patients with AA and those who have no suitable
transplant donor [3]. However, ATG/CSA treatment
requires hospitalization and is often associated with
considerable side effects [3]. In addition, there are
patients who do not respond to ATG/CSA or relapse
after such treatment. In recent years, the mono-
clonal CD52 antibody alemtuzumab has been intro-
duced as a new type of IST in patients with AA and
hypoplastic MDS [5–10]. Alemtuzumab may be ad-
ministered intravenously or subcutaneously in these
patients. However, the protocols for AA and MDS
differ substantially from that used to treat lymphoma
patients. Whereas in lymphoproliferative diseases,
alemtuzumab is often administered in repeated cy-
cles for several months [11], in AA and MDS patients,
the antibody is administered over 5–10 consecutive
days in one cycle which may be followed by treat-
ment with CSA [5–10]. This one-cycle alemtuzumab
regimen is considered to be better tolerated with less
frequent infectious complications.
Several prognostic factors predicting the response
to ATG/CSA in patients with AA and MDS have
been described. In AA, these include cytogenetic
aberrations [12], a (small) paroxysmal nocturnal
hemoglobinuria (PNH) clone [13], age, and ‘prether-
apy’ blood counts [14, 15]. In MDS, the presence of
HLA DR15, younger age, shorter duration of trans-
K Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
original article
Table 1 Bloodandprogenitor cell countsbefore therapy
WBC G/l ANC G/l PLT G/l Hb g/dl Reti G/l CFU-GM/ml BFU-E/ml CFU-GEMM/ml
#1 2.59 1.2 33 11.8 219.1 24 106 6
#2 1.20 0.54 17 10.6 37.7 0 0 0
#3 1.43 0.60 8 7.5 15.1 12 10 0
#4 1.78 0.71 95 9.0 7.1 1849 42 nk
#5 1.33 0.44 11 13.2 36.4 102 37 3
WBC white blood count; ANC absolute neutrophil count; PLT platelet count; Hb hemoglobin level; Reti reticulocyte count; CFU-GM colony-forming unit
granulocyte/macrophage; BFU-E burst-forming unit erythroid, CFU-GEMM colony-forming unit granulocyte/erythrocyte/monocyte/megakaryocyte; nk not known
Table 2 Patients’ characteristics
Diagnosis Gender Age at diagnosis Age at start of alem-
tuzumab
Pretreatment Transfusionsa HLA DR15 Time from diagnosis to
alemtuzumab
#1 f 61 64 none none nt 3 years
#2 f 46 48 ATG/CSA twice 22 + 2 years
#3 m 68 69 ATG/CSA 42 nt 1 year
#4 f 23 44 ATG/CSA, 5-Aza 46 + 21 years
#5 m 52 54 ATG/CSA none nt 2 years
nt not tested; ATG antithymocyte globulin; CSA cyclosporine A; 5-Aza 5-azacitidine
atransfusions: the number of red cell units transfused during one year prior to start of alemtuzumab are depicted
fusion dependence, pancytopenia, low international
prognostic score (IPSS), bone marrow (BM) hypocel-
lularity and—like in AA—the presence of a PNH clone,
have been associated with a better outcome [4, 16–18].
No such prognostic factors have been established for
AA or MDS patients receiving alemtuzumab as IST so
far.
We analyzed ‘pretherapy’ parameters and responses
in five patients with dysplastic/aplastic BM who re-
ceived alemtuzumab as IST.
Patients and methods
Diagnostic evaluations
Data of five patients treated with alemtuzumab were
analyzed retrospectively. Diagnoses (MDS or/and
AA) were established by examining peripheral blood
counts, BM biopsy sections, smears, and karyotyping
before treatment with alemtuzumab. The numbers of
colony-forming progenitor cells (CFU) were studied
in all patients. (Table 1). Moreover, patients were
examined for the presence of a PNH clone by flow
cytometry. The study was approved by the ethics
committee of the Medical University of Vienna.
Patients’ characteristics and pre-alemtuzumab
treatment
Five patients (3 females, 2 males) were included in
our study. Their median age at treatment start (alem-
tuzumab) was 54 years (range 44–69). The time from
first diagnosis to alemtuzumab treatment ranged be-
tween 1 and 21 years (Table 2). AA and MDS were
classified according to published criteria [3, 19, 20].
Four patients had received therapy for AA/MDS
prior to alemtuzumab (patients #2, #3, #4, #5). Two
of them had failed one cycle of ATG/CSA before be-
ing treated with alemtuzumab (#3 and #5), and one
patient had received two cycles of ATG/CSA without
success (#2). The interval between failed ATG/CSA
and alemtuzumab ranged from 6–25 months. Patient
#4 was diagnosed with AA in 1990 and treated with
ATG/CSA in 1998 which led to a complete remission
(CR). After interferon-alpha treatment for hepatitis
C, she relapsed in 2008. However, her relapsed AA
responded well to re-administration of CSA. In 2011
(21 years after first diagnosis) the patient’s disease
evolved to MDS. She was then treated with 5-azac-
itidine, albeit without response, and subsequently
received alemtuzumab. Patient #1 was treated with
alemtuzumab upfront.
Treatment with alemtuzumab
Four patients (#2, #3, #4, #5) received alemtuzumab
according to published protocols for treatment of AA
[5]. In particular, alemtuzumab was administered
subcutaneously in increasing doses, starting with
3 mg on day 1, followed by 10 mg on day 2, and
30 mg on days 3–5, resulting in a total dose of 103 mg
alemtuzumab. Patients #2, #3, and #5 received addi-
tional CSA. The dose of CSA was adjusted to achieve
a blood trough level of 150–200 µg/l. Treatment was
well tolerated, and no dose-reduction or treatment
discontinuation was required. Patient #1 was treated
with alemtuzumab following a protocol described
by Sloand et al. [8] without CSA. After initiation of
treatment with 1 mg on day 1, the patient received
3 mg alemtuzumab on day 2 and 10 mg for addi-
tional 9 days intravenously, amounting to a total dose
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Table 3 Response to alemtuzumab therapyaccording toAAandMDScriteria
AA Natural history Cytogenetics HI-N HI-P HI-E IPSS
#1 NR Failure NR nab – nab 1
#2 PR Stable disease naa + + –c 0.5
#3 PR CR CCR + + + 1
#4 NR Failure nk + + – 1.5
#5 NR Stable disease naa – – nab 0.5
AA aplastic anemia; H-N hematologic improvement neutrophils; HI-P hematologic improvement platelets; HI-E hematologic improvement erythrocytes; IPSS in-
ternational prognostic scoring system; NR no remission, PR partial remission, CR complete remission; CCR complete cytogenetic response; PNH paroxysmal
nocturnal hemoglobinuria; na not applicable; nk not known
aThe karyotype of patients #2 and #5 was normal throughout the course of the disease
bRequired pretreatment levels were not met
cPatient #2 suffered from hemolysis caused by paroxysmal nocturnal hemoglobinuria
of 94 mg alemtuzumab. Premedication consisted of
glucocorticosteroids, paracetamol, and histamine re-
ceptor blockers.
Monitoring of laboratory parameters in the follow-up
Follow-up examinations included complete blood
counts, serum chemistry, and clinical parameters.
In three patients, CFU numbers were recorded in
the follow-up, namely in patients #1, #2, and #3. In
four patients, BM examination was repeated after
alemtuzumab treatment (#1, #2, #3, #5). Chromo-
some analysis was performed in all patients before
therapy; and in three patients (#1, #2, #3), karyotyp-
ing was also performed after alemtuzumab therapy.
GPI-linked surface markers were analyzed in case of
suspected hemolysis (#1, #2, #3, #4).
Response evaluation
Due to the overlapping nature of the diseases recorded
in our patients, responses were classified according
to response criteria proposed for AA as well as pub-
lished response criteria for patients with MDS [21,
22]. Responses according to AA response-criteria
were classified as: complete remission (CR), partial
remission (PR), and no remission (NR). CR was de-
fined as absolute neutrophil count (ANC) >1.5 G/l,
normal hemoglobin (Hb), and platelet counts (PLT)
>150 G/l. A PR required transfusion independence
and no longer meeting criteria for severe disease. Pa-
tients were considered NR when they did not meet
criteria for PR or CR. Responses according to MDS cri-
teria were classified as described by Cheson et al. [22]:
(1) alteration of the natural history of the disease, (2)
cytogenetic response, (3) hematologic improvement.
Progenitor cell assay
Progenitor cell assays were performed using methyl-
cellulose and colony-stimulating cytokines as de-
scribed [23]. Based on morphologic appearance
and size, colonies were classified as colony-form-
ing unit granulocyte/macrophage (CFU-GM), burst-
forming unit erythroid (BFU-E) and colony-forming
unit granulocyte/ erythrocyte/ monocyte/ megakary-
ocyte (CFU-GEMM) .
Immunohistochemistry
Immunohistochemistry was performed on serial sec-
tions prepared from paraffin-embedded, formalin-
fixed BM biopsy specimens using the indirect im-
munoperoxidase staining technique essentially as
described [24, 25]. The following antibodies (Ab) were
applied: anti-CD34 monoclonal Ab (Clone QBEND10,
IgG1 mouse, Novocastra, Newcastle, UK), anti-CXCR4
polyclonal Ab (IgG1 rabbit, Sigma-Aldrich, St. Louis,
MO, USA) and anti-VEGF polyclonal Ab (IgG1 rabbit,
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Results
Primary response to treatment with alemtuzumab
Five patients with MDS or AA received alemtuzumab;
one of these patients was treated with alemtuzumab
upfront (#1), whereas four patients received alem-
tuzumab as second or third line therapy. Two of the
five patients achieved a partial remission following
alemtuzumab treatment (#2 and #3). Time to PR was
3 and 6 months in patients #2 and #3, respectively
according to AA criteria. The other three patients did
not respond to alemtuzumab. The patients’ responses
to alemtuzumab treatment, according to AA and MDS
response criteria, are shown in Table 3.
Posttreatment course and further treatment
As mentioned above, three patients did not respond
to alemtuzumab (#1, #4, #5). Patient #4 died from
pneumonia 4 months after the start of alemtuzumab.
The other two nonresponding patients were further
treated with best supportive care. One patient (#2)
with a PR developed a relapse 15 months after the
start of alemtuzumab. Because of severe thrombo-
cytopenia the patient was treated with eltrombopag,
albeit without response. Since the patient had a
matched unrelated donor and suffered from life-
threatening cytopenia, stem cell transplantation was
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Fig. 1 Responseandoverall survival. Patients#1, #4, and
#5didnot respond to alemtuzumabandpatient #4died from
pneumonia 4monthsafter therapy. Patient #2achievedaPR,
relapsedandsubsequently underwent allogeneicSCT leading
to aCR. In thispatient, eculizumabwasstarted12monthsafter
alemtuzumabandcontinueduntil SCT.Patient #3achieveda
continuousPR. NRno remission;PRpartial remission;RE re-
lapse;CR complete remission;SCT stemcell transplantation
performed. Apart from a moderate graft-versus-host
disease (GvHD), the course was uneventful and the
patient remained in CR during the observation period.
Patient #3 achieved a continuous PR.
Survival and progression-free survival
All patients had regular follow-up investigations in
our departments. Relevant data, including remission
status and disease progression, were collected ap-
proximately 3 months, 6 months, and subsequently
every 6 months after treatment. Patient #3 achieved
a PR 6 months after therapy and remains in PR at
36 months. The other responding patient (#2) had
a relapse 15 months after alemtuzumab. Subse-
quently she successfully underwent allogenic SCT
and achieved a CR from both AA/MDS and PNH.
Three other patients did not respond to alemtuzumab
therapy. Patient #4 succumbed to pneumonia even
though at the time of her death no granulocytopenia
was noted. The MDS of patient #1 progressed to
RAEB-1 approximately 3.5 years after alemtuzumab.
In patient #5, blood counts remained low but stable
and no overt disease progression occurred until he
was lost for follow-up 2 years after alemtuzumab.
Response to alemtuzumab and survival are shown in
Fig. 1.
Short-term and long-term toxicity of alemtuzumab
Alemtuzumab was well tolerated. Mild drug reac-
tions such as pruritus and rash were noted in three
patients (#1, #2, #5). In addition one of them was
treated for arterial hypertension (#1). All symptoms
were readily kept under control and none of the side
effects resulted in dose modifications or treatment in-
terruption. In two patients (#3, #4) no side effects
were noted during and shortly after therapy. Patient
#2 developed a thyroiditis several months after alem-
tuzumab treatment. This condition responded well to
corticosteroids, but led to a permanent impairment of
thyroid function. A relationship between thyre oiditis
and alemtuzumab treatment has been described pre-
viously [9] and therefore cannot be excluded in our
case. Patient #4 died from pneumonia 4 months after
alemtuzumab treatment, despite antiviral and antibi-
otic prophylaxis with valaciclovir and cotrimoxazol. In
the other patients, no life-threatening bacterial or vi-
ral infections were recorded. No secondary neoplasms
were detected in our patients.
Correlation between clinical/laboratory parameters
and treatment responses
No obvious correlations between responses to ther-
apy with alemtuzumab were found when comparing
blood counts, karyotypes, HLA DR15 expression, age,
gender, transfusion burden, and histologic bone mar-
row parameters.
Impact of a concomitant PNH clone
Two patients (#2, #3) developed a PNH clone. In
both cases, the PNH clone was detected after treat-
ment with ATG/CSA and before alemtuzumab ther-
apy. In patient #3, the clone size before therapy was
17% and remained stable at 17 and 21% at 1 year
and 2 years after alemtuzumab start, respectively. A
decrease to 6% in the third year was noted. No sub-
stantial hemolysis occurred in this patient. The PNH
clone size of patient #2 amounted to 60% before alem-
tuzumab therapy and gradually increased to 98% in
the following months. In this patient, a considerable
hemolysis was found, so that eculizumab therapy was
initiated (12 months after alemtuzumab). This pa-
tient was found to respond to eculizumab and was
later transplanted.
Evaluation of colony-forming progenitor cells
Peripheral blood CFU counts were analyzed before
and after alemtuzumab in both responding patients
(#2, #3) as well as in patient #1. In patient #2, CFU
were recorded 2 months prior and 9 months after
alemtuzumab. CFU-GM levels increased from 0/ml
to 6/ml, BFU-E from 0/ml to 70/ml and CFU-GEMM
from 0/ml to 12/ml blood, respectively. Hematologic
relapse was accompanied by a decrease in all CFU-
subsets to 0/ml blood. In patient #3, CFU-GM lev-
els increased from 12/ml to 15/ml blood, BFU-E from
10/ml to 44/ml, and CFU-GEMM from 0/ml to 5/ml
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when comparing CFU counts obtained before alem-
tuzumab treatment with that measured 7months after
therapy. In patient #1, CFU were analyzed 29 months
prior to alemtuzumab treatment and 10 months af-
terwards. CFU-GM increased from 24/ml to 72/ml,
while BFU-E (106/ml vs 6/ml) and CFU-GEMM (6/ml
vs 0/ml) decreased after treatment in this patient.
Histology and immunohistochemistry
Immunostaining of BM sections, using antibodies
against CD34, CXCR4, and VEGF, was performed in
three patients before and after alemtuzumab ther-
apy. Pretreatment sections were hypocellular and
the BM microvessel density was low (Fig. 2). After
therapy, cellularity and microvessel density increased
markedly in both responding patients (#2 and #3).
Surprisingly however, patient #1 who showed no re-
sponse to alemtuzumab as defined by AA and MDS
criteria, also showed an increase in BM cellularity and
microvessel density after treatment (Fig. 2). However,
this patient developed RAEB-1 after therapy.
Cytogenetics
Patients #2 and #5 had a normal karyotype. In pa-
tient #1 a trisomy 8 was detected at diagnosis and the
karyotype remained unchanged after alemtuzumab
treatment. Patient #3 had a normal karyotype at
diagnosis, but developed a 13q- with a subclone car-
rying monosomy 13 after one (unsuccessful) cycle
of ATG/CSA. Following alemtuzumab therapy these
aberrations disappeared.
Analysis in patient #4 revealed a trisomy 8 and as
the disease progressed, an additional isochromosome
17 was detected. No karyotyping was performed after
alemtuzmab treatment in this patient.
Discussion
Alemtuzumab seems to be a promising option for pa-
tients who have not responded to or have relapsed
after ATG/CSA immunosuppression [5–10]. It is un-
clear however, whether there are predictive factors for
response to this regimen. We describe 5 patients with
AA or MDS, who were treated with alemtuzumab. In
two of these patients, a remission was obtained, and
one patient is still in PR after 36 months, whereas
the other patient relapsed and was successfully trans-
planted using allogeneic stem cells. These data con-
firm earlier reports and suggest that alemtuzumab re-
mains a treatment option for patients with relapsing
AA or/and MDS [5–10].
Different criteria for response to treatment have
been described for AA [21] and MDS [22]. However,
it seemed problematic to apply the response classi-
fication proposed by Cheson et al. for MDS [22] in
patients suffering from hMDS. In these patients, blast
cell counts are usually low even before therapy and
therefore cannot be used to quantify a response. Since
the only difference between CR and PR in the MDS
response criteria [22] are blast cell counts (‘altering
the natural history of the disease’), virtually all pa-
tients with improved blood counts that do not reach
the levels for a CR also fail to achieve a PR and have to
be classified as ‘stable disease’ despite their markedly
improved blood counts. Applying response criteria as
published for AA [21] might be a useful alternative for
response evaluation in hMDS. Alternatively, new re-
sponse criteria for hMDS need to be established in
the future.
A variety of prognostic factors for response to IST
with ATG/CSA in AA and MDS have been identified.
These include cytogenetic aberrations [12], ‘prether-
apy’ blood counts [14, 15], and the presence of a PNH
clone [13, 16]. In particular, a small PNH clone has
been linked to superior outcome after ATG/CSA treat-
K Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
original article
ment in AA as well as in MDS patients [13, 16]. In
two of our patients, clonal evolution to overt PNH oc-
curred during ATG/CSA therapy, before alemtuzumab
was initiated. Interestingly, these two patients were
found to achieve a remission in response to alem-
tuzumab. Obviously, larger studies with more patients
are warranted to clarify whether indeed a PNH clone
is indicative of a good response to alemtuzumab sec-
ond-line treatment in hMDS or AA.
So far, little is known about the value of CFU
counting in patients with AA or hMDS in whom IST is
applied [26]. However, it is well known that CFU are
markedly decreased in these patients. In the present
study, we found that pretreatment progenitor cell
counts (but not pretherapy blood counts) correlate
with the response to alemtuzumab in our patients.
In particular, the two patients who responded to
alemtuzumab were those with the lowest prether-
apy progenitor cell counts, and in both, CFU levels
increased during treatment. Again, larger studies
are needed to clarify whether progenitor cell counts
might be a useful tool to identify patients more likely
to profit from alemtuzumab treatment. Thus, it might
be possible to exclude patients unlikely to respond
to alemtuzumab from this therapy and thereby avoid
unnecessary exposure to this IST and the related risk.
Infectious complications are a major concern after
alemtuzumab therapy. Even though the regimens
used to treat AA and MDS are considerable shorter in
duration (treatment-days) than those used for CLL,
the alemtuzumab-induced immunosuppression may
still facilitate infections in AA and MDS patients. No
serious infections were noted in four of our patients,
but one patient died from pneumonia 4 months after
alemtuzumab therapy. It remains unknown however,
whether the pneumonia observed in patient #4 was
related to treatment-induced immunosuppression.
This patient had received standard antiviral and an-
tibiotic prophylaxis after treatment and her neutrophil
count had improved substantially after therapy. No
pathogen was identified. The dramatic rise of this
patient’s neutrophil and platelet counts shortly before
her death was unexpected and may or may not have
be related to alemtuzumab therapy. Another explana-
tion for the improvement of her blood counts could
be a late reaction to prior azacitidine therapy. In addi-
tion, the rising counts may also just have reflected an
acute phase reaction in connection with the infection
that ultimately led to her demise.
Patients in our study were relatively young when
compared to typical MDS populations. However, the
age of our patients (median 54 years, range 44–69)
is similar to that published for other MDS patients
treated with IST [2, 4]. One possibility for the younger
age in these patients (and our patients) may be the
fact that patients with hypoplastic MDS or a MDS-
AA overlap type of disease are younger than other pa-
tients suffering from classical MDS types. An alterna-
tive explanation may be that older patients with such
overlapping disease are no longer considered for in-
terventional therapies and are therefore not referred
to major hematology centers.
The combination of ATG and CSA is considered
standard therapy for AA and hMDS patients who are
not eligible for stem cell transplantation [3, 4]. It is
unknown whether alemtuzumab in combination with
CSA is superior to alemtuzumab alone for treatment
of AA or hMDS. Regimens with and without CSA have
been shown to be effective in this setting [5–10]. In
our study, three patients, including both responding
patients, had received CSA concomitantly with alem-
tuzumab therapy. It seems unlikely that CSA alone
was responsible for the remission in our patients since
both had received CSA after ATG and relapsed while
receiving CSA treatment. However, one might spec-
ulate that the combination of CSA and alemtuzumab
could be superior to alemtuzumab treatment alone.
In conclusion, alemtuzumab can be administered
safely without major side effects and is effective in a
subset of patients with aplastic and/or dysplastic bone
marrow disorders. Therefore, alemtuzumab therapy
should be considered in select patients with hypoplas-
tic MDS. However, larger studies are needed to deter-
mine the efficacy and risk of long-term complications
of alemtuzumab treatment in AA/MDS patients and to
predict what subsets of patients would indeed benefit
from this therapy.
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